Abstract:Recent progress in understanding the genetic basis of many psychiatric diseases has identified rare and common variants responsible for genetic risk. Integrating epigenomics data from disease-relevant cell types and tissues promises to enhance interpretation of these risk variants and the mechanisms by which they confer disease liability. A better understanding of the role of non-coding regulatory DNA and variation in histone modification in mediating the effects of genetic risk variants promises to give insights into the molecular mechanisms underlying psychiatric disease. With this goal in mind, the PsychENCODE Consortium generated a large-scale epigenomics resource for the human brain to serve as a foundation for integrative genomics in psychiatric research. We performed ChIP-Seq on 17 subjects, 2 brain regions, 2 cell types and 2 histone marks that yielded 136 total ChIP-Seq samples. Of these 129 (n=63 H3K4me3; n=66 H3K27ac) passed quality control. For each combination of brain region, cell type and histone mark, reads from corresponding samples were combined into a consolidated subset of the data. This produced 8 consolidated subsets, corresponding to: ACC-neuronal-H3K4me3, PFC-neuronal-H3K4me3, etc. The entire data set was then processed and analyzed through the annotation, peak calling, covariate and pathway analyses pipeline. We have generated the largest cell type-specific dataset of histone-modification in the human brain to date across two brain cortical regions, composed of reference maps from 129 samples collected from 17 healthy subjects. These reference maps consist of ChIP-Seq for two histone marks associated with promoters and active enhancers, H3-trimethyl-lysine 4 (H3K4me3) and H3-acetyl-lysine 27 (H3K27ac) from either neurons, or surrounding non-neuronal cells. Analysis of this data has revealed unexplored insights into cell-, brain region- and to a lesser extent, subject- and sex-specific histone methylation and acetylation landscapes shaping the epigenome of the adult human cerebral cortex. We identify multiple loci with robust region-specific differences separating prefrontal from cingulate neurons, and numerous genome loci with extraordinary high inter-individual variability in H3K27ac and H3K4me3. Finally, we found a significant enrichment of risk variants for schizophrenia, educational attainment and depressive symptoms only in neuronal markers, further indicating the importance of conducting cell type-specific epigenome studies. Risk variants for schizophrenia, depressive symptoms, neuroticism and educational years are significantly enriched in genomic loci marked specifically in neuronal cells. The difference between neuronal and non-neuronal cells is the major axis of variation in histone modification, yet many genomic loci show substantial epigenetic variability across subjects and brain regions. These findings highlight the utility of this NIMH PsychENCODE-sponsored resource to elucidate epigenomic architectures of regulatory and disease-associated non-coding DNA in the human brain.

Cell type‐specific DNA methylation analysis of the prefrontal cortex of patients with schizophrenia

DNA Methylation in Schizophrenia: Progress and Challenges

Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients

Genome-wide DNA methylation risk scores for schizophrenia derived from blood and brain tissues further explain the genetic risk in patients stratified by polygenic risk scores for schizophrenia and bipolar disorder

DNA methylation analysis of BDNF gene promoters in peripheral blood cells of schizophrenia patients

Genome-wide DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia in the Chinese Han population

Large-scale analysis of DNA methylation identifies cellular alterations in blood from psychosis patients and molecular biomarkers of treatment-resistant schizophrenia

CELL-SPECIFIC HISTONE MODIFICATION MAPS LINK SCHIZOPHRENIA RISK TO THE NEURONAL EPIGENOME

Genome-wide analysis of DNA methylation in 106 schizophrenia family trios in Han Chinese

Genome-wide methylome analyses reveal novel epigenetic regulation patterns in schizophrenia and bipolar disorder

Epigenome-wide Meta-Analysis of Blood DNA Methylation and Its Association with Subcortical Volumes: Findings from the ENIGMA Epigenetics Working Group

Integrating brain methylome with GWAS for psychiatric risk gene discovery

Hyper-Coordinated DNA Methylation is Altered in Schizophrenia and Associated with Brain Function

Genome-wide DNA Methylation Analysis in Families with Multiple Individuals Diagnosed with Schizophrenia and Intellectual Disability.

Quantitative DNA Methylation Analysis of DLGAP2 Gene Using Pyrosequencing in Schizophrenia with Tardive Dyskinesia: A Linear Mixed Model Approach.

The DNA Methylation Profile Within the 5′-Regulatory Region of DRD2 in Discordant Sib Pairs with Schizophrenia

The association of DNA methylation and brain volume in healthy individuals and schizophrenia patients

Genome-wide DNA methylation analysis in schizophrenia with tardive dyskinesia: a preliminary study

Psychotic symptoms associated increased CpG methylation of metabotropic glutamate receptor 8 gene in Chinese Han males with schizophrenia and methamphetamine induced psychotic disorder: a longitudinal study

Genes implicated by a methylome-wide schizophrenia study in neonatal blood show differential expression in adult brain samples

Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder